JPRN-UMIN000030892已完成2 期
Phase 2 trial of first-line combination therapy of cisplatin, pemetrexed and nivolumab in participants with unresectable malignant pleural mesothelioma - Phase 2 trial of first-line combination therapy of cisplatin, pemetrexed and nivolumab in participants with unresectable malignant pleural mesothelioma
Okayama Rosai Hospital0 个研究点目标入组 18 人开始时间: 2018年1月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with history of anaphylaxis induced by other drugs 2) Autoimmune disease 3) Double cancer 4) Metastasis to brain or meninges 5) Interstitial lung disease or pulmonary fibrosis 6) Diverticulitis or peptic ulcer 7) Pleural effusion necessary for emission every 2 weeks or more 8) Treating pericardial effusion or ascites 9) Uncontrollable tumor pain 10) Transient ischemic attack, cerebrovascular accident, thrombosis or thromboembolism within 180 days 11) Uncontrollable severe cardiovascular disease 12) Anticoagulant therapy 13) Uncontrollable diabetes 14) Treating systemic infection 15) Transplantation therapy 16) Obviously positive to HIV infection 17) HTLV-1 antibody positive, HBs antigen positive or HCV antibody positive. Either HBs antigen positive or HBc antibody positive and HBV-DNA detection although HBs antigen is negative. 18) History of treatment for T cell regulation 19) Surgery with local or surface anesthesia within 14 days 20) Surgery with general anesthesia within 28 days 21) Pleurodesis within 14 days 22) Pleurodesis using picibanil within 28 days 23) Adhesions surgery of pericardium or peritoneum 24) Radiation therapy for pain relief within 14 days 25) Radiopharmaceutical therapy within 56 days 26) Administration of unapproved drugs within 28 days or unapproved antibody within 90 days 27) Administration of systemic adrenal cortical hormone or immunosuppressive agents 28) Females who are or may be pregnant or lactating 29) Patients who are incapable of giving consent (for example, dementia) 30) Any other inadequacy for this study
研究者
相似试验
已完成
2 期
Phase II clinical trial of combination therapy with medium-chain triglycerides and ghrelin in patients with chronic obstructive pulmonary diseaseCOPDJPRN-UMIN000015222ational Hospital Organization Toneyama National Hospital10
尚未招募
不适用
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30
进行中（未招募）
不适用
Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor (ATX-study) - ATXEUCTR2006-006058-83-NLVU Medisch Centrum
已完成
不适用
A study to evaluate the safety and tolerability of doxorubicin and durvalumab, in patients with advanced soft tissue sarcoma.KCT0003577Yonsei University Health System, Severance Hospital45
招募中
2 期
A randomised phase II trial of combined therapy with CPT-11/CDDP versus CPT-11 alone in second-line treatment of advaneced or recurrent gastric cancer resistant to Docetaxel/Cisplatin/TS-1 (DCS) therapyGastric CancerJPRN-UMIN000003141Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)80